Olumiant(baricitinib)
Baricitinib, Olumiant (baricitinib) is a small molecule pharmaceutical. Baricitinib was first approved as Olumiant on 2017-02-13. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1 and tyrosine-protein kinase JAK2. In addition, it is known to target cyclin-G-associated kinase, non-receptor tyrosine-protein kinase TYK2, BMP-2-inducible protein kinase, AP2-associated protein kinase 1, and tyrosine-protein kinase JAK3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Olumiant (discontinued: Baricitinib)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| baricitinib | Use Authorization | 2022-05-10 |
| olumiant | New Drug Application | 2023-03-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BARICITINIB, OLUMIANT, ELI LILLY AND CO | |||
| 2025-06-13 | I-890 | ||
| 2025-05-10 | I-891 | ||
| 2023-05-31 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
162 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | 4 | 14 | 8 | 11 | 37 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 4 | 11 | 9 | 10 | 35 |
| Covid-19 | D000086382 | — | — | — | 8 | 18 | 1 | 5 | 28 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 1 | 1 | 8 | 1 | 6 | 17 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | 8 | 1 | 6 | 16 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | 8 | 1 | 3 | 13 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | 1 | 1 | 3 | 1 | 1 | 6 |
| Alopecia | D000505 | HP_0002293 | L64 | 1 | 1 | 3 | 1 | 1 | 6 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | — | 1 | 2 | 3 |
| Spondylarthritis | D025241 | — | — | — | 1 | — | 1 | 1 | 3 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | — | — | 5 | 4 | — | — | 7 |
| Syndrome | D013577 | — | — | 1 | 4 | 2 | — | 1 | 6 |
| Skin diseases | D012871 | — | L00-L99 | — | 3 | 2 | — | 1 | 5 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | 1 | 3 | — | — | 4 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 2 | 2 | — | — | 4 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 2 | 1 | — | 1 | 4 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | — | 3 | — | — | 3 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 2 | — | — | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | 1 | — | — | 2 |
| Fever | D005334 | HP_0001945 | R50.9 | — | 1 | 1 | — | 1 | 2 |
Show 23 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | 2 | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 3 | — | — | — | 3 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 3 | — | — | — | 3 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 3 | — | — | — | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 3 | — | — | — | 3 |
| Vitiligo | D014820 | EFO_0004208 | L80 | — | 1 | — | — | 1 | 2 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | 1 | 2 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | 1 | 1 | — | — | 1 | 2 |
| Myositis | D009220 | EFO_0000783 | G72.49 | — | 2 | — | — | — | 2 |
| Muscular diseases | D009135 | HP_0003198 | G72.9 | — | 2 | — | — | — | 2 |
Show 51 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 16 | — | — | — | — | 16 |
| Allergic contact dermatitis | D017449 | — | L23 | 1 | — | — | — | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | — | — | — | 1 |
| Contact dermatitis | D003877 | — | L25 | 1 | — | — | — | — | 1 |
| Delayed hypersensitivity | D006968 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Liver failure | D017093 | HP_0001399 | K72.9 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | — | — | — | 1 | 1 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
| Rheumatic diseases | D012216 | — | M79.0 | — | — | — | — | 1 | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | — | — | — | 1 | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
| Eosinophilia | D004802 | HP_0001880 | D72.1 | — | — | — | — | 1 | 1 |
| Immunoglobulin g4-related disease | D000077733 | — | D89.84 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Baricitinib |
| INN | baricitinib |
| Description | Baricitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis. It has a role as an antirheumatic drug, an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an anti-inflammatory agent, an immunosuppressive agent and an antiviral agent. It is a pyrrolopyrimidine, a member of pyrazoles, a member of azetidines, a sulfonamide and a nitrile. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1 |
Identifiers
| PDB | — |
| CAS-ID | 1187594-09-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105759 |
| ChEBI ID | — |
| PubChem CID | 44205240 |
| DrugBank | DB11817 |
| UNII ID | ISP4442I3Y (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,423 documents
View more details
Safety
Black-box Warning
Black-box warning for: Olumiant
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,601 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use